Market watchers are catching on to what's been flying under the radar: months of regulatory pressure on pharma suddenly eased when the administration softened its stance. That shift alone was enough to flip investor sentiment on the entire sector. Turns out the pharmaceutical industry wasn't actually in decline—it's been growing the whole time. The real story wasn't about the fundamentals; it was about perception. When policy headwinds ease, capital flows, and the market begins to recognize what was always there. That's a classic setup for overlooked sectors making a comeback.